1. Whole-tumour evaluation with MRI and radiomics features to predict the efficacy of S-1 for adjuvant chemotherapy in postoperative pancreatic cancer patients: a pilot study
   Liang Liang et al, 2021, BMC Medical Imaging CrossRef
2. DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer
   Hiroyuki Kato et al, 2021, Carcinogenesis CrossRef
3. PD-1 immunotherapy in pancreatic cancer: current status
   Ning Pu et al, 2019, Journal of Pancreatology CrossRef
4. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
   Shigehiro Tsukahara et al, 2022, Scientific Reports CrossRef
5. Signaling Pathways Involved in 5-FU Drug Resistance in Cancer
   Fahima Danesh Pouya et al, 2022, Cancer Investigation CrossRef
6. Dihydropyrimidine Dehydrogenase Levels in Colorectal Cancer Cells Treated with a Combination of Heat Shock Protein 90 Inhibitor and Oxaliplatin or Capecitabine
   Mahshid Mohammadian et al, 2019, Advanced Pharmaceutical Bulletin CrossRef